Literature DB >> 31808869

Evidence-Based Minireview: Perioperative management of the VWD patient at elevated thrombotic risk.

Holleh D Husseinzadeh1, Sandra Haberichter2,3.   

Abstract

Entities:  

Year:  2019        PMID： 31808869      PMCID： PMC6913468          DOI： 10.1182/hematology.2019000078

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN： 1520-4383


× No keyword cloud information.
  11 in total

1.  Venous thromboembolism in von Willebrand disease.

Authors:  P M Mannucci
Journal:  Thromb Haemost       Date:  2002-09       Impact factor: 5.249

2.  Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Susan R Kahn; Wendy Lim; Andrew S Dunn; Mary Cushman; Francesco Dentali; Elie A Akl; Deborah J Cook; Alex A Balekian; Russell C Klein; Hoang Le; Sam Schulman; M Hassan Murad
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Thromboembolic incidence with transiently elevated levels of coagulation factors in patients with von Willebrand disease treated with VWF:FVIII concentrate during surgery.

Authors:  J C Gill; P M Mannucci
Journal:  Haemophilia       Date:  2014-08-12       Impact factor: 4.287

4.  Efficacy and safety of a VWF/FVIII concentrate (wilate® ) in inherited von Willebrand disease patients undergoing surgical procedures.

Authors:  A Srivastava; M Serban; S Werner; B A Schwartz; C M Kessler
Journal:  Haemophilia       Date:  2016-12-27       Impact factor: 4.287

5.  Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand's disease.

Authors:  M Makris; B Colvin; V Gupta; M L Shields; M P Smith
Journal:  Thromb Haemost       Date:  2002-09       Impact factor: 5.249

Review 6.  Impact of early mobilization protocol on the medical-surgical inpatient population: an integrated review of literature.

Authors:  Lavanya Pashikanti; Diane Von Ah
Journal:  Clin Nurse Spec       Date:  2012 Mar-Apr       Impact factor: 1.067

Review 7.  Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies.

Authors:  A Coppola; M Franchini; M Makris; E Santagostino; G Di Minno; P M Mannucci
Journal:  Haemophilia       Date:  2012-02-15       Impact factor: 4.287

8.  von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA).

Authors:  W L Nichols; M B Hultin; A H James; M J Manco-Johnson; R R Montgomery; T L Ortel; M E Rick; J E Sadler; M Weinstein; B P Yawn
Journal:  Haemophilia       Date:  2008-03       Impact factor: 4.287

9.  A second retrospective database analysis confirms prior findings of apparent increased cardiovascular comorbidities in hemophilia A in the United States.

Authors:  Thomas J Humphries; Alice Ma; Craig M Kessler; Rajesh Kamalakar; Jennifer Pocoski
Journal:  Am J Hematol       Date:  2016-04-07       Impact factor: 10.047

Review 10.  Role of ambulation to prevent venous thromboembolism in medical patients: where do we stand?

Authors:  Maria Chiara Chindamo; Marcos Arêas Marques
Journal:  J Vasc Bras       Date:  2019-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.